RubrYc Therapeutics
iBio is a biotechnology company focused on developing next-generation antibody therapeutics for cardiometabolic diseases, obesity, and difficult-to-treat cancers. Their proprietary AI-driven discovery platform, which includes an Epitope Engineering Engine, Antibody Library, StableHu™ Antibody Optimizer, EngageTx™, and ShieldTx®, allows for precision antibody identification and optimization. The company aims to create therapeutics that preserve muscle mass during weight loss, prevent weight regain, and treat associated heart conditions, potentially complementing existing treatments like GLP-1s. Their pipeline also includes immuno-oncology candidates for various cancers. iBio emphasizes a collaborative approach for partnering and advancing its pipeline assets.
RubrYc Therapeutics
iBio is a biotechnology company focused on developing next-generation antibody therapeutics for cardiometabolic diseases, obesity, and difficult-to-treat cancers. Their proprietary AI-driven discovery platform, which includes an Epitope Engineering Engine, Antibody Library, StableHu™ Antibody Optimizer, EngageTx™, and ShieldTx®, allows for precision antibody identification and optimization. The company aims to create therapeutics that preserve muscle mass during weight loss, prevent weight regain, and treat associated heart conditions, potentially complementing existing treatments like GLP-1s. Their pipeline also includes immuno-oncology candidates for various cancers. iBio emphasizes a collaborative approach for partnering and advancing its pipeline assets.